BR112014029597A2 - compostos de cromano - Google Patents
compostos de cromanoInfo
- Publication number
- BR112014029597A2 BR112014029597A2 BR112014029597A BR112014029597A BR112014029597A2 BR 112014029597 A2 BR112014029597 A2 BR 112014029597A2 BR 112014029597 A BR112014029597 A BR 112014029597A BR 112014029597 A BR112014029597 A BR 112014029597A BR 112014029597 A2 BR112014029597 A2 BR 112014029597A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- disease
- prevention
- treatment
- alzheimer
- Prior art date
Links
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 abstract 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- -1 chroman compounds Chemical class 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653321P | 2012-05-30 | 2012-05-30 | |
| US201361782038P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/043016 WO2013181202A2 (en) | 2012-05-30 | 2013-05-29 | Chromane compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014029597A2 true BR112014029597A2 (pt) | 2017-11-07 |
Family
ID=49674034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014029597A BR112014029597A2 (pt) | 2012-05-30 | 2013-05-29 | compostos de cromano |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8975415B2 (https=) |
| EP (1) | EP2854797A4 (https=) |
| JP (1) | JP2015518048A (https=) |
| KR (1) | KR20150023536A (https=) |
| CN (1) | CN104394862A (https=) |
| AR (1) | AR091203A1 (https=) |
| AU (1) | AU2013267555A1 (https=) |
| BR (1) | BR112014029597A2 (https=) |
| CA (1) | CA2873678A1 (https=) |
| EA (1) | EA026380B1 (https=) |
| HK (1) | HK1208817A1 (https=) |
| MX (1) | MX2014014066A (https=) |
| SG (1) | SG11201407796YA (https=) |
| TW (1) | TW201408672A (https=) |
| WO (1) | WO2013181202A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015518048A (ja) | 2012-05-30 | 2015-06-25 | コメンティス， インコーポレイテッド | クロマン化合物 |
| TW201629025A (zh) * | 2014-10-07 | 2016-08-16 | 阿斯特捷利康公司 | 化合物及其作為ｂａｃｅ抑制劑之用途 |
| CN110818694B (zh) * | 2019-11-18 | 2023-04-21 | 上海医药工业研究院有限公司 | 艾拉普林中间体及其应用 |
| CN110724135B (zh) * | 2019-11-18 | 2023-04-28 | 上海医药工业研究院有限公司 | 一种艾拉普林中间体及其制备方法 |
| CN110713483B (zh) * | 2019-11-18 | 2023-04-07 | 上海医药工业研究院 | 艾拉普林中间体及艾拉普林的制备方法 |
| CN110790753B (zh) * | 2019-11-18 | 2023-04-07 | 上海医药工业研究院 | 艾拉普林对甲苯磺酸盐、其制备方法和应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1196609A2 (en) | 1999-06-28 | 2002-04-17 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
| US20040121947A1 (en) | 2000-12-28 | 2004-06-24 | Oklahoma Medical Research Foundation | Compounds which inhibit beta-secretase activity and methods of use thereof |
| CA2464736A1 (en) | 2001-10-23 | 2003-05-15 | Oklahoma Medical Research Foundation | Beta-secretase inhibitors and methods of use |
| PT1699455E (pt) | 2003-12-15 | 2013-08-27 | Merck Sharp & Dohme | Inibidores de protease de aspartilo heterocíclicos |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| EP2318416B1 (en) | 2008-07-28 | 2013-09-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| WO2010013302A1 (ja) * | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| JP5444240B2 (ja) * | 2008-07-28 | 2014-03-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| US8450308B2 (en) * | 2008-08-19 | 2013-05-28 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| CA2736130C (en) * | 2008-09-11 | 2014-01-14 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
| CA2753730C (en) * | 2009-03-13 | 2020-12-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| WO2011072064A1 (en) * | 2009-12-08 | 2011-06-16 | Array Biopharma Inc. | S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors |
| CN102812005B (zh) * | 2010-02-24 | 2014-12-10 | 生命医药公司 | β-分泌酶抑制剂 |
| EP2547685A1 (en) * | 2010-03-15 | 2013-01-23 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta - secretase modulators |
| MX2012010657A (es) * | 2010-03-15 | 2013-02-07 | Amgen Inc | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. |
| US20120065195A1 (en) * | 2010-03-31 | 2012-03-15 | Clark Christopher T | Compounds for treating neurodegenerative diseases |
| WO2011130741A1 (en) | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
| US20120083501A1 (en) | 2010-09-24 | 2012-04-05 | Hunt Kevin W | Compounds for treating neurodegenerative diseases |
| TW201300380A (zh) | 2010-10-19 | 2013-01-01 | Comentis Inc | 抑制β－分泌酶活性之噁二唑化合物及其使用方法 |
| WO2012071458A1 (en) | 2010-11-22 | 2012-05-31 | Array Biopharma Inc. | Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases |
| EP2643325A1 (en) | 2010-11-23 | 2013-10-02 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
| US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| EP2673279A1 (en) | 2011-02-07 | 2013-12-18 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
| EP2675810A1 (en) | 2011-02-15 | 2013-12-25 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
| US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| EP2780321B1 (en) | 2011-10-10 | 2015-12-30 | Astrazeneca AB | Mono-fluoro beta-secretase inhibitors |
| JP2015518048A (ja) | 2012-05-30 | 2015-06-25 | コメンティス， インコーポレイテッド | クロマン化合物 |
| EP2669286A1 (en) | 2012-05-31 | 2013-12-04 | Ares Trading S.A. | Spiro tetrahydro-benzothiophen derivatives useful for the treatment of neurodegenerative diseases |
-
2013
- 2013-05-29 JP JP2015515133A patent/JP2015518048A/ja active Pending
- 2013-05-29 SG SG11201407796YA patent/SG11201407796YA/en unknown
- 2013-05-29 KR KR20147036874A patent/KR20150023536A/ko not_active Withdrawn
- 2013-05-29 CA CA2873678A patent/CA2873678A1/en not_active Abandoned
- 2013-05-29 BR BR112014029597A patent/BR112014029597A2/pt not_active IP Right Cessation
- 2013-05-29 CN CN201380028374.8A patent/CN104394862A/zh active Pending
- 2013-05-29 MX MX2014014066A patent/MX2014014066A/es unknown
- 2013-05-29 EA EA201492271A patent/EA026380B1/ru not_active IP Right Cessation
- 2013-05-29 HK HK15109582.8A patent/HK1208817A1/xx unknown
- 2013-05-29 EP EP13797843.3A patent/EP2854797A4/en not_active Withdrawn
- 2013-05-29 AR ARP130101885 patent/AR091203A1/es unknown
- 2013-05-29 AU AU2013267555A patent/AU2013267555A1/en not_active Abandoned
- 2013-05-29 WO PCT/US2013/043016 patent/WO2013181202A2/en not_active Ceased
- 2013-05-30 TW TW102119181A patent/TW201408672A/zh unknown
-
2014
- 2014-02-27 US US14/192,667 patent/US8975415B2/en not_active Expired - Fee Related
-
2015
- 2015-01-22 US US14/603,110 patent/US9242973B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20150225386A1 (en) | 2015-08-13 |
| AU2013267555A1 (en) | 2014-12-04 |
| US8975415B2 (en) | 2015-03-10 |
| EA026380B1 (ru) | 2017-04-28 |
| HK1208817A1 (en) | 2016-03-18 |
| TW201408672A (zh) | 2014-03-01 |
| KR20150023536A (ko) | 2015-03-05 |
| EP2854797A4 (en) | 2016-01-13 |
| US9242973B2 (en) | 2016-01-26 |
| EA201492271A1 (ru) | 2015-10-30 |
| EP2854797A2 (en) | 2015-04-08 |
| US20140179695A1 (en) | 2014-06-26 |
| JP2015518048A (ja) | 2015-06-25 |
| CN104394862A (zh) | 2015-03-04 |
| CA2873678A1 (en) | 2013-12-05 |
| WO2013181202A3 (en) | 2014-01-30 |
| MX2014014066A (es) | 2015-03-19 |
| WO2013181202A2 (en) | 2013-12-05 |
| SG11201407796YA (en) | 2014-12-30 |
| AR091203A1 (es) | 2015-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013027670A2 (pt) | "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory" | |
| BR112014018879A8 (pt) | Composto e composição farmacêutica e combinação compreendendo dito composto | |
| BR112014026703A2 (pt) | inibidores de dna-pk | |
| UY35391A (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| BR112015010663A2 (pt) | formas de dosagem de ruxolitinib de liberação sustentada | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
| BR112015012197A2 (pt) | terapia de combinação | |
| BR112015007814A2 (pt) | diagnóstico, prevenção e tratamento de doenças da articulação | |
| EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
| BR112013004766A2 (pt) | 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| BR112014029597A2 (pt) | compostos de cromano | |
| BR112013019256A2 (pt) | inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
| BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
| EA201400973A1 (ru) | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств | |
| BR112015019919A2 (pt) | compostos bicíclicos | |
| UA109414C2 (uk) | Арильовані камфени та фармацевтична композиція на їх основі | |
| EP2886112A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF EYE DISEASES WITH S-ALLYL-L-CYSTEIN AS AN ACTIVE AND PHARMACEUTICAL FORMULATION THEREWITH | |
| EA201591021A1 (ru) | 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний | |
| BR112015011693A2 (pt) | composições fibrinolíticas compreendendo bromelina e nattokinase para a prevenção e tratamento de estados flebotrombóticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law | ||
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |